Skip to main content

Main menu

  • Home
  • About
    • Clinical Chemistry
    • Editorial Board
    • Most Read
    • Most Cited
    • Alerts
    • CE Credits
  • Articles
    • Current Issue
    • Early Release
    • Future Table of Contents
    • Archive
    • Browse by Subject
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Advertisers
    • Permissions & Reprints
  • Resources
    • AACC Learning Lab
    • Clinical Chemistry Trainee Council
    • Clinical Case Studies
    • Clinical Chemistry Guide to Scientific Writing
    • Clinical Chemistry Guide to Manuscript Review
    • Journal Club
    • Podcasts
    • Q&A
    • Translated Content
  • Abstracts
  • Submit
  • Contact
  • Other Publications
    • The Journal of Applied Laboratory Medicine

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out

Search

  • Advanced search
Clinical Chemistry
  • Other Publications
    • The Journal of Applied Laboratory Medicine
  • Subscribe
  • My alerts
  • Log in
  • Log out
Clinical Chemistry

Advanced Search

  • Home
  • About
    • Clinical Chemistry
    • Editorial Board
    • Most Read
    • Most Cited
    • Alerts
    • CE Credits
  • Articles
    • Current Issue
    • Early Release
    • Future Table of Contents
    • Archive
    • Browse by Subject
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Advertisers
    • Permissions & Reprints
  • Resources
    • AACC Learning Lab
    • Clinical Chemistry Trainee Council
    • Clinical Case Studies
    • Clinical Chemistry Guide to Scientific Writing
    • Clinical Chemistry Guide to Manuscript Review
    • Journal Club
    • Podcasts
    • Q&A
    • Translated Content
  • Abstracts
  • Submit
  • Contact
OtherTechnical Brief

Stability of Ketamine and Its Metabolites Norketamine and Dehydronorketamine in Human Biological Samples

Youssef Hijazi, Magali Bolon, Roselyne Boulieu
Published September 2001
Youssef Hijazi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magali Bolon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roselyne Boulieu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Ketamine is a NMDA receptor antagonist used since 1970 for the induction of anesthesia. It has a rapid onset and short duration of action, so it is a preferred agent for short-term surgical procedures. Ketamine possesses sedative and analgesic properties and maintains hemodynamic stability; it therefore is used in patients during the neuro-reanimation period (1). Ketamine produces posthypnotic emergence reactions, such as prolonged hallucination and delirium. The frequency of ketamine abuse is increasing (2), and fatal ketamine poisoning cases have been reported (3)(4).

Ketamine is metabolized by the hepatic microsomal cytochrome P450 enzymes to two major metabolites, norketamine (NK) and dehydronorketamine (DHNK), which are further biotransformed to glucuronide conjugates and then excreted in the urine (5). The activities of these metabolites have not been well studied in humans, but in animals, it was reported that they possess an anesthetic effect and that they might be responsible for the emergent reactions to ketamine anesthesia (5). In view of the growing importance of ketamine, both as a therapeutic agent and more recently as a drug of abuse, we studied the stability of ketamine and its two major metabolites, NK and DHNK, in biological samples under various conditions to optimize the conditions for transport and storage of these biological samples. Little has been reported about the stability of ketamine and its metabolites in human blood samples. In a recent study, ketamine was found to be stable in plasma samples stored at −20 °C for up to 3 months (6). In this study, the stability of ketamine metabolites was not investigated. Idvall et al. (7) reported that ketamine and its metabolites were stable in plasma samples stored at −20 °C for up to 2 months.

To date, no data on the stability of ketamine and its metabolites in human blood are available, so we proposed to investigate the stability of these compounds in human blood samples under different storage conditions. We studied the stability of ketamine and its metabolites NK and DHNK in human serum stored at −20 °C for 6 months and at 4 °C for 2 days. The stability of these compounds in human blood stored at 4 and 20 °C for 2 h was also examined.

Ketamine, NK, DHNK, and nortilidine (internal standard) were generously supplied by Parke-Davis Laboratories. Lyotrol® drug-free human serum was obtained from Biomerieux. Solvents for the extraction procedure and for HPLC (Uvasol grade), potassium dihydrogen phosphate, and boric acid were purchased from Merck. Ketamine, NK, and DHNK were analyzed according to the chromatographic method described by Bolze and Boulieu (8). The chromatographic system consisted of a Waters 715 Ultrawisp injector connected to a 510 series pump and coupled to a PDA 996 photodiode array detector and a COMPAQ Pentium III computer. The column used was a reversed-phase silica gel end-capped Purospher® RP-18e (125 × 4 mm; 5 μm bead size) purchased from Merck. The samples were extracted according to a published procedure (8). Briefly, 0.5 mL of the biological sample was alkalinized with boric acid (pH 13) and extracted twice with a mixture of dichloromethane-ethyl acetate (80:20 by volume) followed by a back-extraction with 2 mol/L HCl. After evaporation of the acid layer and reconstitution of the residue with mobile phase, 60 μL was injected into the HPLC column.

To study the stability of ketamine and its metabolites in stock solutions, we prepared aqueous solutions of ketamine, NK, DHNK, and nortilidine at a concentration of 500 μg/L. The solutions were stored at −80 °C and analyzed in five replicates at time zero (t0) and every 2 weeks of storage up to 6 months.

To study the stability of ketamine and its metabolites in human serum stored at −20 and 4 °C, we added ketamine, NK, and DHNK at a concentration of 500 μg/L to a pool of human serum (Lyotrol). For the stability study at −20 °C, we divided a serum sample into six 3-mL aliquots and stored them at −20 °C. Aliquots were analyzed in five replicates at t0 and every 2 weeks of storage up to 10 weeks. For the stability study at 4 °C, 3-mL aliquots were drawn at t0 and at 2, 4, 6, 8, 10, 24, 30, and 48 h and immediately stored at −20 °C until analysis. The assay was performed within 15 days of storage, and five replicates were used in each case.

The stability of the compounds of interest was also assessed in human blood left at room temperature or at 4 °C. Ketamine, NK, and DHNK at a concentration of 500 μg/L were added to blood samples from volunteers. The samples were divided into two aliquots: one was stored at room temperature (∼20 °C) and the other at 4 °C. At t0 and at 30, 60, and 120 min, 8 mL of each aliquot was removed and immediately centrifuged at 2000g for 10 min at 20 °C. The plasma was decanted and stored immediately at −20 °C until analysis. The assay was performed within 15 days of storage, and five replicates were used in each case. Results were compared using the nonparametric Mann-Whitney test. Two-tailed values <0.05 were considered significant. Statistical analysis was performed using Graphpad Instat software.

Ketamine, NK, DHNK, and nortilidine were stable in aqueous solutions at −80 °C for at least 6 months. These solutions were used for the addition experiments in biological samples. No significant difference was observed in the concentrations of ketamine and its metabolites in human serum left at 4 °C for 2 days. Storage of ketamine, NK, and DHNK in human serum at −20 °C did not produce significant changes in concentrations over a period of 10 weeks. These data are in accordance with those reported previously (7). As shown in Table 1⇓ , plasma concentrations of ketamine and NK remained constant when the centrifugation of blood was delayed for 2 h, and the stability of the two compounds was not affected by the change in storage temperature from 4 to 20 °C. On the other hand, a significant decrease in the plasma DHNK concentration was observed when blood samples were kept at 4 °C, whereas surprisingly, the DHNK concentration did not change significantly when blood samples were left for 2 h at room temperature.

After 30 min of storage at 4 °C, the plasma concentration of DHNK was, on average, 68% of the initial concentration. Furthermore, we also observed that the plasma concentrations of DHNK measured at t0 represented, on average, only 75% of the concentration added to blood and stored at 4 °C or at room temperature. These results could suggest that DHNK is unequally distributed between plasma and blood cells and that rapid permeation of this compound into blood cells may occur. Chemical degradation is not likely because the increase in temperature from 4 to 20 °C slowed the decrease in DHNK concentrations. Further investigations should be done to study the effect of various temperatures on the plasma concentration of DHNK. Moreover, the determination of DHNK concentrations in blood cells to estimate the partitioning behavior of this compound may be warranted.

In conclusion, the present study shows the necessity of observing rigorous conditions for the accurate estimation of ketamine metabolite concentrations in blood samples. The collected blood should be centrifuged without delay at ambient temperature to avoid the decrease in DHNK concentrations, which is most likely attributable to the permeation of this compound into the blood cells. The plasma samples can be transported at 4 °C within 2 days and can be stored at −20 °C for 10 weeks without any change in the concentrations of ketamine, NK, and DHNK.

View this table:
  • View inline
  • View popup
Table 1.

Stability of ketamine and its metabolites in human blood.

  • © 2001 The American Association for Clinical Chemistry

References

  1. ↵
    White PF, Way WL, Trevor AJ. Ketamine—its pharmacology and therapeutic use. Anaesthesiology 1982;56:119-136.
    OpenUrlPubMed Order article via Infotrieve
  2. ↵
    Lawrence J. Drug intelligence report: ketamine abuse increasing. Microgram 1991;29:202.
  3. ↵
    Licata M, Pierini G. A fatal ketamine poisoning. J Forensic Sci 1994;39:1314-1320.
    OpenUrlPubMed Order article via Infotrieve
  4. ↵
    Moore KA, Kilbane EM, Jones R, Kunsman GW, Levine B, Smith M. Tissue distribution of ketamine in a mixed drug fatality. J Forensic Sci 1997;2:1183-1185.
    OpenUrl
  5. ↵
    Adams JD, Baillie TA, Trevor AJ, Castagnoli N. Studies on the biotransformation of ketamine. 1. Identification of metabolites produced in vitro from rat liver microsomal preparations. Biomed Mass Spectrom 1981;8:527-538.
    OpenUrlCrossRefPubMed Order article via Infotrieve
  6. ↵
    Gross AS, Nocolay A, Eschalier A. simultaneous analysis of ketamine and bupivacaine in plasma by high performance liquid chromatography. J Chromatogr 1999;728:107-115.
    OpenUrl
  7. ↵
    Idvall J, Ahlgren I, Aronsen KF, Stenverg P. Ketamine infusions: pharmacokinetics and clinical effects. Br J Anaesth 1979;51:1167-1173.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Bolze S, Boulieu R. HPLC determination of ketamine, norketamine, and dehydronorketamine in plasma with a high purity reversed phase sorbent. Clin Chem 1998;44:560-564.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

Clinical Chemistry: 47 (9)
Vol. 47, Issue 9
September 2001
  • Table of Contents
  • Index by author
Print
Share
Stability of Ketamine and Its Metabolites Norketamine and Dehydronorketamine in Human Biological Samples
Youssef Hijazi, Magali Bolon, Roselyne Boulieu
Clinical Chemistry Sep 2001, 47 (9) 1713-1715;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Stability of Ketamine and Its Metabolites Norketamine and Dehydronorketamine in Human Biological Samples
Youssef Hijazi, Magali Bolon, Roselyne Boulieu
Clinical Chemistry Sep 2001, 47 (9) 1713-1715;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Detection of Factor VIII Gene Mutations by High-Resolution Melting Analysis
  • Effects of 7 Hemoglobin Variants on the Measurement of Glycohemoglobin by 14 Analytical Methods
  • Mass Spectrometry–Based Detection of Hemoglobin E Mutation by Allele-Specific Base Extension Reaction
Show more Technical Briefs

Similar Articles

Subjects

  • SUBJECT AREAS
    • General Clinical Chemistry
    • Drug Monitoring and Toxicology

Options

  • Home
  • About
  • Articles
  • Information for Authors
  • Resources
  • Abstracts
  • Submit
  • Contact
  • RSS

Other Publications

  • The Journal of Applied Laboratory Medicine
Footer logo

© 2019 American Association for Clinical Chemistry

Powered by HighWire